: iStockAnalyst.com Symbols Feed

Wall Street Slips On Disappointing Confidence Data, CIT (NYSE: CIT) Rallies

Tue, 29 Sep 2009 22:27:37 GMT

US stocks finished lower on Tuesday after weaker-than-expected consumer confidence data rekindled economic fears.[More...]

Pre-Market: Caution Returns To Wall Street - Stock Futures Indicate Modestly Lower Start

Tue, 29 Sep 2009 13:15:00 GMT

Stock futures remain modestly lower though off their worst pre-market levels. Stocks look to resume a period of consolidation after taking a break by posting strong, deal-fueled gains on Monday.[More...]

US Stock Futures Decline Ahead Of Data, MBIA Inc (NYSE: MBI) In Focus

Tue, 29 Sep 2009 12:43:12 GMT

US stock futures pointed to a weaker start on Tuesday as investors remained cautious ahead of release of key housing and consumer data.[More...]

Stocks Of The Day: AMR, COL, SQNM, EK, DFS

Thu, 17 Sep 2009 19:13:07 GMT

US stocks were trading in a very narrow range on Thursday, as investors remained cautious following three days of gains.[More...]

Rally Refuses To Give Way

Tue, 04 Aug 2009 22:23:21 GMT

We certainly had another up-day, but it all came in the last 20 minutes or so. The market opened lower in the morning, rallied steadily until mid-day to new highs, getting up to 1007 on the S&P 500. The indices then rolled over, but the SPX managed to hold 1000 three times in the afternoon, while the NDX also held support around the 1618 area, near the morning lows. A last 20-minute short-covering frenzy took the market up sharply and they closed in the plus column. Net on the day the Dow closed up 33.63 to 9320.19, the S&P 500 up 3.02 to 1005.65, and the Nasdaq 100 up just 0.37 at 1628.49. However, that was 12 points off its low. Advance-declines were 3 to 2 positive on New York and about 4 to 3 positive on Nasdaq. Up/down volume was better than 2 to 1 positive on New York on total volume of 1 1/4 billion. Nasdaq traded over 2.1 billion and had a 4 to 3 positive volume[More...]

Lear (LEA) Prepares to File For Bankruptcy

Thu, 25 Jun 2009 23:46:22 GMT

As we said a month ago in (Jun 4, 2009: Detroit's Woes Wound an Army of Suppliers) I think many people do not understand the daisy chain that is the automotive industry - there are countless suppliers of various size. They have been in a "right sizing" for a decade now, decimating the ranks (we've lost about half of them as we offshore) but there are still literally thousands out there. Lost in the "headline news" of the week (green shoots mind you) was the bankruptcy of Visteon (yes last week) - which was spun off of Ford much like Delphi (in bankruptcy[More...]

Guess The Federal Bailout, Win Money

Wed, 10 Jun 2009 17:33:00 GMT

It appears we are back to 2008 type trading; guess what the government is going to bailout next, and place your bets. The only irony in watching these stocks soar is knowing people in the supplier industry and these companies themselves and realizing what shape they are in, while their stocks surge. As we said last week, (Jun 4, 2009: Detroit's Woes Wound an Army of Suppliers) there will be a lot of fallout in the multi thousand supplier base but as with banks, it appears the government will protect the largest. And this is exactly the type of information having a bevy of friends from Goldman Sachs within government provides - you know exactly where to place your chips. Not that this type of thing ever happens. And we wonder how Goldman had only 8 losing days on their trading desk in all of first quarter 2009. (talent of course, not information flow) If you want some[More...]

Can Sequenom (SQNM) Make It Back Into Investors's Good Graces?

Tue, 02 Jun 2009 16:20:51 GMT

Still keeping my eye on the Sequenom (SQNM) - but the whole idea with this name was to avoid the small cap "biotech" bipolar experience (either a huge win or a huge loss). Unfortunately, this is what this has now turned to, a coin flip. Probably the most bizarre disclosure I've ever been associated with, and I've seen many off the wall things in my years in the market. Per CBSMarketwatch Shares of beleaguered biotech Sequenom Inc. got a much-needed boost last week in the form of a somewhat favorable report issued by Lazard Capital Markets, but is the stock really that seaworthy?Sequenom jumped nearly 15% on May 27, after Lazard analyst Sean Lavin upgraded the stock, now trading in the $3 range, to hold from sell, saying he[More...]

Sequenom (NasdaqGM: SQNM) Splattered, EXACT Sciences (NasdaqCM: EXAS) On The Rise

Wed, 06 May 2009 12:11:06 GMT

With Sequenom (SQNM) losing about three-quarters of its market value in pre-market trading to around 3 bucks per share; EXACT Sciences (EXAS) is poised to continue its comeback from penny stock levels late last year and has a chance to close the year at a[More...]

Myriad Generics (MYGN) Slight Miss On Revenue; Beats On Earnings

Mon, 04 May 2009 22:04:27 GMT

As always, you can tell a lot from the stock price action ahead of earnings because in the nearly SEC free Wild Wild West atmosphere "those in the know" act before you will. Myriad Genetics (MYGN) has been weak for the past two weeks, falling below the 50 day moving average 2 weeks ago on 3 days of high volume selling (see those 3 big red bars in the volume column in late April?). Ding ding - we have a winner; the "important people" were exiting the stage starting in the $44s.... [More...]

Kellogg, Kodak, MGM Mirage, Exxon Mobil big movers

Thu, 30 Apr 2009 22:24:00 GMT

The world's largest cereal maker said its first-quarter profit increased on cost cutting measures and beat analyst estimates.
Eastman Kodak Co., down 59 cents at $3.05
An analyst upgraded the casino operator and boosted the company's price target on its first-quarter results and regional presence.

[More...]

SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights

Thu, 06 Aug 2009 19:56:00 GMT

SEQUENOM, Inc. , today reported its financial results for the quarter ended June 30, 2009.[More...]

SEQUENOM Announces August 6 Webcast of Financial and Other Business Results

Thu, 30 Jul 2009 17:55:00 GMT

SEQUENOM, Inc. , will report second quarter 2009 and year-to-date financial results after market close on Thursday, August 6, 2009. The company will conduct a conference call and an audio webcast at 1:30 pm Pacific Time on the same day.[More...]

SEQUENOM Announces Launch of MassARRAY Compact 96 System

Mon, 27 Jul 2009 20:26:00 GMT

SEQUENOM, Inc. today announced the launch of the MassARRAY Compact 96 system.[More...]

University of Michigan Study Shows SEQUENOM's MassARRAY Technology Identifies HPV Infections Missed by Standard Hybridization Test

Mon, 13 Jul 2009 20:25:00 GMT

Results from a study published by the University of Michigan have shown that as many as 15% of women in the study group determined to be negative for the presence of human papillomavirus in the cervix, via the most commonly used test for HPV DNA, may actually be infected with the virus at clinically relevant viral loads. PCR-MS detected the presence of high-risk HPV in nearly half of women who tested negative by the Hybrid Capture 2 test, which is standard of care in many countries. Approximately 9,000 American women are diagnosed with cervical cancer each year despite regular cervical screening. The study, titled, Development and Evaluation of a PCR and Mass Spectroscopy-based Method for Quantitative, Type-specific Detection of Human Papillomavirus, will be published in the September 2009 edition of Journal of Virological Methods. The assay used in this study is exclusively licensed by SEQUENOM .'We found that nearly half of the 75 women who had been called HPV-negative by the HC2 test had detectable levels of HPV DNA by the PCR-MS method,' said Divya Patel, PhD, MPH, of the University of Michigan, one of the study investigators, and lead author of the recently published paper. 'More importantly, because the PCR-MS method also measures the quantity of HPV relative to the number of human cells in the sample, or 'viral load,' we determined that about 15% of these samples had HPV loads comparable to the HPV loads found in women called HPV-positive by the HC2 test. While further work to define clinically meaningful HPV detection thresholds is required, our results suggest that a type-specific, quantitative PCR-MS based test may be an important advance in the early detection of cervical cancer.' Study Methodology199 cervical scrapings from women who had been routinely screened for HPV DNA using the HC2 test, the most widely used clinical HPV test, and 77 tissue samples taken from tumors in confirmed cervical cancer patients were analyzed using a prototype assay developed by the late Dr. David Kurnit at the University of Michigan HPV assay).Utilizing SEQUENOM's proprietary MassARRAY) system that couples standard polymerase chain reaction techniques with mass spectrometry , study samples were simultaneously screened, genotyped and quantified for each of 13 HPV genotypes highly associated with cervical cancer.Results SummaryNearly half of the 75 cervical scraping samples that were negative for high-risk HPV by the HC2 test were positive by PCR-MS, and approximately 15% of these samples contained a higher viral load than the clinically validated cut-off of the HC2 test.Eighteen of 124 cervical scraping samples that were positive by HC2 for high-risk HPV were negative by PCR-MS. In all these cases, degenerate DNA sequencing failed to detect any of the 13 high-risk HPV types included in the HC2 test, reflecting false positive results in the HC2 test. 'This is another example of how the precision of PCR-MS can be applied to solve important medical and scientific problems,' said Charles Cantor, PhD, chief scientific officer of SEQUENOM. 'Showing exceptional analytical performance in a proof-of-concept study is a significant step in designing an assay with great clinical performance. The hybridization techniques used today, simply cannot match the state-of-the-art analytical performance found with PCR-MS.'We are very excited about the future prospects for the AttoSense HPV test, particularly the potential to close the last major gap in screening for cervical cancer and thus possibly saving thousands of lives,' Dr. Cantor continued. 'We are moving forward to utilize the capabilities of our MassARRAY platform to improve this test further, as having an assay that shows great standalone potential as well as the possibility of combining with other tests for HPV could play a key role in HPV genotyping. We believe that the AttoSense HPV test could be an important addition to our growing women's health portfolio and is another example of our commitment to improving the health of women around the world.'About HPVIn the US alone, over 55 million women are screened each year for cervical cancer at a cost of more than $2 billion. If detected early, available treatments are extremely effective in preventing the onset of cervical cancer. For more than 60 years, the well known 'Pap smear' was the primary method for detecting early signs of cervical cancer. While this test has dramatically reduced the incidence of cervical cancer over the years, it typically misses about 10-20% of cases that should be further evaluated. Physicians have long known that HPV infection in the cervix is associated with nearly 100% of cervical cancers. A decade ago, the first test for HPV DNA, the HC2 test, was approved by the FDA to be used along with the Pap smear to better identify patients at risk for cervical cancer. Today, more than 10 million HPV DNA tests are conducted annually, and the total number of HPV DNA tests is growing at a rate exceeding 35% per year. Many have predicted a HPV DNA test capable of genotyping and quantifying HPV DNA will one day supplant the Pap smear as the primary screening test for cervical cancer. Yet, although HPV DNA tests have further reduced the incidence of cervical cancer in the US, there are still approximately 9,000 new cases and 4,000 deaths from cervical cancer each year.About AttoSenseThe AttoSense HPV assay detects, identifies, and quantifies each of 15 HPV types associated with cervical cancer in a single reaction. Preliminary research studies show that the test can measure and reproducibly detect as few as 50 DNA copies for each of the 15 HPV genotypes in liquid cytology samples from cervical smears and tissue biopsy samples. The AttoSense test is currently available for Research Use Only. SEQUENOM intends to seek FDA and EU approvals as soon as practical. SEQUENOM will continue to collaborate with major medical centers to further validate and demonstrate the performance and value of the AttoSense HPV test.About MassARRAYSEQUENOM's proprietary MassARRAY system is a high performance matrix assisted laser desorption/ionization time-of-flight mass spectrometry-based nucleic acid analysis platform that quantitatively measures genetic target material and its variations in a rapid, accurate, and cost efficient manner. SEQUENOM's MassARRAY system facilitates a number of nucleic acid analysis applications including single nucleotide polymorphism genotyping and allelotyping, copy number variation analysis, quantitative gene expression analysis, quantitative methylation marker analysis, comparative sequence analysis of haploid organisms, SNP discovery, and oligonucleotide quality control.About SEQUENOMSEQUENOM is a life sciences company committed to providing the best genetic analysis products that translate the results of genomic science into solutions for molecular diagnostics, biomedical research, translational research and molecular medicine applications. As an industry innovator in DNA detection technology, SEQUENOM's MassARRAY system allows a direct mass measurement of nucleic acids, providing unparalleled precision and quantification. On the diagnostics front, SEQUENOM is developing a comprehensive portfolio of prenatal test methods by combining the versatility of the MassARRAY system with the company's SEQureDx technology, which enables the detection of circulating cell-free fetal nucleic acids in a maternal blood sample. The company is also developing tests for oncology, infectious diseases and other disorders. The company was founded in 1994 and is headquartered in San Diego, California. For more information please visit http://www.sequenom.com.SEQUENOM), AttoSense, SEQureDx, and MassARRAY) are trademarks of SEQUENOM, Inc. All other trademarks and service marks are the property of their respective owners.Additional investigators: Yang-Jen Shih, Duane W. Newton, Claire W. Michael, Paul A. Oeth, Michael D. Kane, Anthony W. Opipari, Mack T. Ruffin, IV, Linda M. Kalikin, and David M. Kurnit.This work was supported in part by grants from the Mary Kay Ash Charitable Foundation , SensiGen, LLC , and the National Cancer Institute of the National Institutes of Health [K24 CA080846 , K07 CA120040 ].Forward-Looking Statements Except for the historical information contained herein, the matters set forth in this press release, including statements regarding potential false negatives and such potential false negatives leading to cervical cancer, publication of the study in the September 2009 edition of Journal of Virological Methods, further work to define clinically meaningful HPV detection thresholds, the suggestion that a type specific quantitative PCR-MS based test may be an important advance in the early detection of cervical cancer, the future prospects and potential of the AttoSense HPV test, improvements to the test, the potential of the AttoSense HPV test and combining it with other tests and its role in HPV genotyping, the Company's growing women's health portfolio and the addition of the test to that portfolio, whether a HPV DNA test capable of genotyping and quantifying HPV DNA will one day supplant the Pap smear as the primary screening test for cervical cancer, the Company's intentions to seek FDA and EU approval for the test as soon as practical, the Company's plans to continue to collaborate with major medical centers to further validate and demonstrate the performance and value of the test, and the Company's ability to develop prenatal tests and tests for oncology, infectious diseases and other disorders, are forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with the Company's ability to develop and commercialize new technologies and products, particularly new technologies such as HPV DNA diagnostics and laboratory developed tests, reliance upon the collaborative efforts of other parties, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, and other risks detailed from time to time in the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and periodic reports and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.[More...]

Pomerantz Reminds Sequenom, Inc. Investors of Tuesday, June 30 Deadline

Thu, 25 Jun 2009 17:26:00 GMT

Investors in Sequenom, Inc. , have until Tuesday, June 30 to submit a request to the Court to be appointed Lead Plaintiff in the class action. Pomerantz Haudek Grossman & Gross LLP filed a class action lawsuit in the United States District Court, Southern District of California, against the Company and certain of its top officials. The class action was filed on behalf of those who purchased securities of the Company between June 4, 2008 and April 29, 2009, inclusive . The Complaint alleges violations of Sections 10 and 20 of the Securities Exchange Act and Rule 10b-5 promulgated thereunder.[More...]

Kendall Law Group, Led By a Former Federal Judge and U.S. Attorney, Reminds Investors About the Upcoming Lead Plaintiff Deadline in the Sequenom Case

Mon, 15 Jun 2009 23:13:00 GMT

On May 1, 2009, several securities class actions were filed against Sequenom (NASDAQ: SQNM).
As a result, investors who purchased Sequenom shares have until June 30, 2009, to request lead plaintiff status.
Consistently, the Defendants reported that clinical results concerning the trials for the drug were extremely favorable, with 100% detection and no false positives, compared to only 70-90% detection and 5% false positives in competing tests.

[More...]

Ann D. White Law Offices, P.C. Announces That a Securities Class Action Lawsuit Has Been Filed Against Sequenom, Inc.

Sat, 13 Jun 2009 00:04:00 GMT

A class action lawsuit was filed in the United States District Court for the Southern District of California against Sequenom, Inc. (NASDAQ: SQNM).
The class period is from June 4, 2008 through April 29, 2009.
Defendants consistently reported that clinical results concerning the Down Syndrome test trials for the product were extremely favorable, with 100% detection and no false positives.

[More...]

Pomerantz Reminds Sequenom, Inc. Investors of June 30 Deadline -- SQNM

Fri, 05 Jun 2009 21:14:00 GMT

Investors in Sequenom, Inc. have until June 30, 2009 to submit a request to be appointed Lead Plaintiff in the class action. Pomerantz Haudek Grossman & Gross LLP filed a class action lawsuit in the United States District Court, Southern District of California, against the Company and certain of its top officials. The class action was filed on behalf of those who purchased securities of the Company between June 4, 2008 and April 29, 2009, inclusive . The Complaint alleges violations of Sections 10 and 20 of the Securities Exchange Ace and Rule 10b-5 promulgated thereunder.[More...]

INVESTOR ALERT: Former Attorney General of Louisiana Charles C. Foti, Jr. and KSF Notify Sequenom, Inc. Investors of Lead Plaintiff Application Deadline in Securities Fraud Class Action Lawsuit -- SQNM

Wed, 27 May 2009 23:34:00 GMT

NEW ORLEANS, LA -- -- 05/27/09 -- Kahn Swick & Foti, LLC announces that investors have only until June 30, 2009 to apply for lead plaintiff in a securities fraud class action lawsuit filed in the United States District Court for the Southern District of California, on behalf of purchasers of the common stock of Sequenom, Inc. between June 4, 2008 and April 29, 2009, inclusive . No class has yet been certified in this action.[More...]

Holzer Holzer & Fistel, LLC Announces It Has Filed a Shareholder Class Action Against Sequenom, Inc. (NASDAQ: SQNM)

Wed, 27 May 2009 15:57:00 GMT

ATLANTA, GA -- -- 05/27/09 -- Holzer Holzer & Fistel, LLC announces it has filed a class action lawsuit in the United States District Court for the Southern District of California on behalf all persons or entities who purchased shares of Sequenom, Inc. between June 4, 2008 and April 29, 2009 .[More...]